KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to -$1.3 billion.

  • Teva Pharmaceutical Industries' Other Non-Current Assets fell 2047.1% to -$1.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$1.3 billion, marking a year-over-year decrease of 2047.1%. This contributed to the annual value of -$1.3 billion for FY2025, which is 2047.1% down from last year.
  • As of Q4 2025, Teva Pharmaceutical Industries' Other Non-Current Assets stood at -$1.3 billion, which was down 2047.1% from $1.8 billion recorded in Q3 2025.
  • In the past 5 years, Teva Pharmaceutical Industries' Other Non-Current Assets registered a high of $1.8 billion during Q2 2025, and its lowest value of -$1.5 billion during Q4 2023.
  • In the last 5 years, Teva Pharmaceutical Industries' Other Non-Current Assets had a median value of $464.5 million in 2024 and averaged $406.5 million.
  • As far as peak fluctuations go, Teva Pharmaceutical Industries' Other Non-Current Assets crashed by 44580.5% in 2023, and later soared by 32442.4% in 2025.
  • Teva Pharmaceutical Industries' Other Non-Current Assets (Quarter) stood at $515.0 million in 2021, then dropped by 14.37% to $441.0 million in 2022, then plummeted by 445.8% to -$1.5 billion in 2023, then increased by 27.61% to -$1.1 billion in 2024, then dropped by 20.47% to -$1.3 billion in 2025.
  • Its last three reported values are -$1.3 billion in Q4 2025, $1.8 billion for Q3 2025, and $1.8 billion during Q2 2025.